Mark W. Frohlich
CIK: 0001420482
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)3 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
RIGL
RIGEL PHARMACEUTICALS INC
Director
Discretionary Trading P&L
Holdings
About Frohlich Mark W
Frohlich Mark W (SEC CIK 0001420482) files insider reports with the SEC as Director of RIGEL PHARMACEUTICALS INC (RIGL).
Signal8 holds 4 ownership filings by Frohlich Mark W (1 Form 3, 3 Form 4), filed between Mar 10, 2025 and May 19, 2026. Those filings report 3 transactions, from Mar 6, 2025 to May 15, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Frohlich Mark W's filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by Frohlich Mark W
Other insiders filing for RIGEL PHARMACEUTICALS INC (RIGL)
- Schorno Dean L, EVP & Chief Financial Officer
- Santos David A, EVP, Chief Commercial Officer
- RODRIGUEZ RAUL R, CEO, President
- Furey Raymond J., EVP, GC, CCO & Corp Sec
- HANNAH ALISON L., EVP, Chief Medical Officer
- Ali-Jackson Kamil, Director